- Home
- FAMI vs RDHL Comparison
FAMI vs RDHL Comparison
Compare FAMI & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FAMI | RDHL |
|---|---|---|
| Founded | 2015 | 2009 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6M | 4.0M |
| IPO Year | 2017 | 2012 |
Fundamental Metrics
Financial Performance| Metric | FAMI | RDHL |
|---|---|---|
| Price | $0.12 | $0.61 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 54.6M | 2.6M |
| Earning Date | 08-04-2025 | 04-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $381.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.09 | $0.57 |
| 52 Week High | $2.05 | $2.79 |
Technical Indicators
Market Signals| Indicator | FAMI | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 41.82 | 42.50 |
| Support Level | $0.09 | N/A |
| Resistance Level | $0.20 | $0.85 |
| Average True Range (ATR) | 0.04 | 0.11 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 6.13 | 1.69 |
Price Performance
Historical ComparisonAbout FAMI Farmmi Inc.
Farmmi Inc is an investment holding company. Through its subsidiaries, it acts as a supplier of agricultural products. It is an agricultural technology enterprise focused on its supply chain platform by promoting edible mushroom products and agriculture technology. Its product offerings include tapioca, corn, red dates, shiitake mushrooms, mu er fungus, other edible fungi, and other agricultural products. Geographically, the company's products are sold in China, Southeast Asia, Japan, North America, Europe and the Middle East under the Forasen and Farmmi brands.
About RDHL Redhill Biopharma Ltd.
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.